Reig Jofre launches first dietary supplement for female androgenetic alopecia

Complidermol 5α PLUS tackles not only the known hormonal factor, but also the oxidative and inflammatory factors, new pathophysiological factors identified as causes of this condition.

Reig Jofre has over 10 years’ experience in the treatment of FAA and is market leader in Spain. Complidermol 5α PLUS results from combining two key strategic areas for Reig Jofre – dermatology and dietary supplements – where the company is widening its approach to healthcare through prevention.

Following an in-depth review of the scientific literature on this condition, experts have concluded that, in addition to the genetic and hormonal factors known and treated to date in FPB, there are also other factors which can be considered responsible for this condition, such as oxidative stress and micro-inflammation in the affected area.

Complidermol 5α PLUS has an increased effect on the known hormonal factor and in addition treats these newly-identified pathophysiological factors, which play a part in the shrinkage of hair follicles characteristic of this condition.

Complidermol 5α PLUS has been developed to slow down the progression of FAA, revitalise the hair follicle and lengthen the anagen phase of hair growth. The aim is to improve hair quality and the quality of life of women suffering from this condition.

FAA currently affects around 40% of women over 50 and accounts for 3% to 8% of first appointments with dermatologists. It is an issue which significantly affects the psychological wellbeing and quality of life of women affected – statistics reveal that it is an area of concern for 52% of them, whereas only 28% of men consider hair loss to be a problem.

The peak reached in this age group due to lower oestrogen activity after menopause is the main reason for hormonal factors having been the primary therapeutic target up until now, along with genetic factors. However, a review of new scientific evidence has led experts to focus on these new factors, which Complidermol 5α PLUS is the first to address.

It is a new milestone for Reig Jofre and its R&D department, through which the company places all its scientific expertise at the service of patients to offer innovative dermatological treatments, a therapeutic area in which, along with gynaecology, Reig Jofre specialises.

Reig Jofre's dermatology range accounted for 13% of the company's total sales in 2015 (last year reported), reaching 20.4 million euros, a 22% increase over the previous year.

This new formulation is now being launched in Spain, but the company does not rule out launching it in other markets in the future.